Flamel Technologies (FLML) Misses Q1 EPS by 10c

Flamel Technologies (NASDAQ: FLML) reported Q1 EPS of $0.04, $0.10 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $36.2 million versus the consensus estimate of $34 million.

The Company is maintaining its full year 2016 revenue guidance of $110 - $130 million and expects the recently acquired FSC products, AcipHex Sprinkle", Karbinal" ER, Cefaclor for Oral Suspension and Flexichamber", to contribute revenues in the range of $10 - $15 million. As a result of the multiple clinical trials expected to run throughout 2016, the Company expects research & development expenses to be in the range of $35 - $50 million, up from $25.6 million in 2015.

For earnings history and earnings-related data on Flamel Technologies (FLML) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c